Literature DB >> 17431851

Analysis of a binary composite endpoint with missing data in components.

Hui Quan1, Daowen Zhang, Ji Zhang, Laure Devlamynck.   

Abstract

Composite endpoints are often used in clinical trials in order to increase the overall event rates, reduce the sizes of the trials and achieve desired power. For example, in a trial to study the effect of a treatment on the prevention of venous thromboembolic events after a major orthopaedic surgery of the lower limbs, the primary endpoint is usually a composite endpoint consisting of any deep vein thrombosis identified by systematic venography of lower limbs, symptomatic and well-documented non-fatal pulmonary embolism, and death from all causes. Just as any endpoints, missing data can occur in the components of the composite endpoint. If a patient has missing data on some of the components but not all the components, this patient may not have complete data but partial data for the composite endpoint. To be consistent with the intention-to-treat principle, the patient should not be discarded from the analysis. In this research, we propose an approach for the analysis of a composite endpoint with missing data in components. The main idea is to first derive the probabilities of all possible study outcomes based on the appropriate model and then to construct the overall rate for the composite endpoint. Simulations are conducted to compare the approach with several naïve methods. A data example is used to illustrate the application of the approach.

Entities:  

Mesh:

Year:  2007        PMID: 17431851     DOI: 10.1002/sim.2893

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.

Authors:  Richard F Potthoff; Susan Halabi
Journal:  Pharm Stat       Date:  2015-04-20       Impact factor: 1.894

2.  Comparison of proportions for composite endpoints with missing components.

Authors:  Xianbin Li; Brian S Caffo
Journal:  J Biopharm Stat       Date:  2011-03       Impact factor: 1.051

3.  Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

Authors:  Alexander Thomas Cohen; Theodore Erich Spiro; Harry Roger Büller; Lloyd Haskell; Dayi Hu; Russell Hull; Alexandre Mebazaa; Geno Merli; Sebastian Schellong; Alex Spyropoulos; Victor Tapson
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

4.  Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.

Authors:  José N Boada; Carlos Boada; Mar García-Sáiz; Marcelino García; Eduardo Fernández; Eugenio Gómez
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

Review 5.  A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.

Authors:  Fowzia Ibrahim; Brian D M Tom; David L Scott; Andrew Toby Prevost
Journal:  Trials       Date:  2016-06-02       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.